Hamilton, Erika http://orcid.org/0000-0002-1911-0336
Cortes, Javier
Ozyilkan, Ozgur
Chen, Shin-Cheh
Petrakova, Katarina
Manikhas, Aleksey
Jerusalem, Guy
Hegg, Roberto
Huober, Jens
Zhang, Wei
Chen, Yanyun
Martin, Miguel
Clinical trials referenced in this document:
Documents that mention this clinical trial
nextMONARCH Phase 2 randomized clinical trial: overall survival analysis of abemaciclib monotherapy or in combination with tamoxifen in patients with endocrine-refractory HR + , HER2– metastatic breast cancer
https://doi.org/10.1007/s10549-022-06662-9
Funding for this research was provided by:
Eli Lilly and Company
Article History
Received: 25 April 2022
Accepted: 18 June 2022
First Online: 12 July 2022
Declarations
:
: E.H. is a full-time employee of Sarah Cannon Research Institute. J.C. declares Consulting/Advisor: Roche, Celgene, Cellestia, AstraZeneca, Seattle Genetics, Daiichi Sankyo, Erytech, Athenex, Polyphor, Lilly, Merck Sharp&Dohme, GSK, Leuko, Bioasis, Clovis Oncology, Boehringer Ingelheim, Ellipses, Hibercell, BioInvent, Gemoab, Gilead, Menarini, Zymeworks, Reveal Genomics; Honoraria: Roche, Novartis, Celgene, Eisai, Pfizer, Samsung Bioepis, Lilly, Merck Sharp&Dohme, Daiichi Sankyo; Stock, patents and intellectual property: MedSIR, Nektar Pharmaceuticals; and Travel, accommodation, expenses: Roche, Novartis, Eisai, pfizer, Daiichi Sankyo, Astrazeneca. O.O. has nothing to declare. S-C.C. has nothing to declare. K.P. has nothing to declare. A.M. has nothing to declare. G.J. declares Non-Financial Support from Eli Lilly and company during the conduct of the study; Grants, Personal Fees and Non-Financial Support: Novartis, Roche, Pfizer; Personal Fees and Non-Financial Support: Eli Lilly and company, Amgen, BMS, Astra-Zeneca; Personal Fees: Abbvie, Seagen, Daiichi-Sankyo; Non-Financial Support: Medimmune, MerckKGaA outside the submitted work. R.H. has nothing to declare. J.H. declares Research Funding: Celgene, Novartis, Hexal, Lilly; Honoraria: Lilly, Novartis, Roche, Pfizer, AstraZeneca, MSD, Celgene; Eisai, Abbvie, Seagen, Gilead; Consulting, advisory relationship: Lilly, Novartis, Roche, Pfizer, Hexal, AstraZeneca, MSD, Celgene, Abbvie, Seagen, Gilead; and Travel expenses: Roche, Pfizer, Novartis, Celgene, Daiichi. W.Z. was a full-time employee of Eli Lilly and Company at the time of the study and is an Eli Lilly and Company shareholders. Y.C.is a full-time employee of Eli Lilly and Company and Eli Lilly and Company shareholders. M.M. declares Research Grants: Roche, PUMA and Novartis; Consulting/Advisory fees: AstraZeneca, Amgen, Taiho Oncology, Roche/Genentech, Novartis, PharmaMar, Eli Lilly and Company, PUMA, Taiho Oncology, Daiichi Sankyo and Pfizer; and Speakers’ honoraria: AstraZeneca, Eli Lilly and Company, Amgen, Roche/Genentech, Novartis, and Pfizer.
: The study was approved by the local ethical and institutional review boards for all participating sites and was conducted according to the Declaration of Helsinki’s Good Clinical Practice. This study followed the Consolidated Standards of Reporting Trials (CONSORT) reporting guideline.
: All patients provided written informed consent before enrollment.